The Ledger ResearchPrivate

The Front Office

Scouting report · HELP

Michael I. Halstead

  • Chief Executive Officer and Director, HELP since 2026-08src

Ex-President of Intra-Cellular Therapies; Helus Pharma CEO since August 2026

—thin record

Not ranked yet

Scouting sheet

as of 24 Sep 2026
Delivers guidance—no promises on the record yet
Answers the question—no call reviewed yet
Capital allocation—company five-year record: neutral — inherited: the five-year record is mostly a predecessor's
Pay design—tsr, time only
Skin in the game—no holding or price on file
Age
53src
In the role
1 mo
Promises scored
0
Hit rate
—
Dodges / 100 answers
—
Airtime on calls
—
Every promise, oldest firstno scored promises yet

What to weigh

Watch 3

  • Arrived 2026-08-03 as the fourth person to run the company in eleven months, a few months before the Q4 2026 APPROACH Phase 3 readoutsrc
  • 28.4% of votes withheld on his first election as director on 2026-09-22src
  • His salary, bonus target and any sign-on terms are not disclosed in any document read; the circular pre-dates his first pay yearsrc

In their favour 2

  • Put about $1.35m of his own money into the stock (100,000 shares at a $13.47 average) on 2026-09-21src
  • Has done the clinical-to-commercial transition in the same therapeutic area (CNS, adjunctive MDD) at Intra-Cellularsrc

Career

  1. 2026-08 – now
    Cybin Inc. (Helus Pharma)src
    Chief Executive Officer; director from 2026-09-22
  2. 2024-03 – 2025-04
    Intra-Cellular Therapiessrc
    President
    Promoted 2024-03-19; the Helus release says he led the $14.6bn sale to Johnson & Johnson, which closed in April 2025 per PR-2026-08-18
  3. 2019-01 – 2024-03
    Intra-Cellular Therapiessrc
    Executive Vice President, General Counsel & Secretary
  4. 2014-07 – 2018-12
    Intra-Cellular Therapiessrc
    Senior Vice President, General Counsel & Secretary
    Joined 2014-07-29
  5. 2005-07 – 2013-12
    Warner Chilcott plcsrc
    Leadership positions, finishing as SVP Corporate Development (corporate development, legal, HR)
    Directed the $3bn purchase of Procter & Gamble's pharmaceutical business (2009) and the $8.5bn sale to Actavis (2013), per PR-2026-08-03

Undated in the sources

  • Davis Polk & Wardwellsrc, Corporate associate, M&A group

Not located: January to July 2014 (between Warner Chilcott and Intra-Cellular) and April 2025 to August 2026 (after the J&J closing) not located in any source searched; the Davis Polk years are not dated

Achievements

  • Spent more than a decade at Intra-Cellular Therapies, from general counsel to President, as CAPLYTA was developed, approved and launchedsrc
  • Led Intra-Cellular's $14.6bn sale to Johnson & Johnsonsrc
  • At Warner Chilcott, led the $3bn acquisition of P&G's pharmaceutical business and worked on the $8.5bn sale to Actavissrc
  • Bought 100,000 Helus shares on the open market on 2026-09-21, seven weeks after joiningsrc

Education

  • Boston University, BA International Relationssrc
  • Villanova University Charles Widger School of Law, JD Lawsrc

Background

  • Other Trained as a lawyer; his career has been in legal, corporate development and general management, and Helus is his first CEO rolesrc
  • Other Has brought in former Intra-Cellular colleagues: Regina Donohue as Chief People Officer and Suresh Durgam, Intra-Cellular's former CMO, to the Scientific Advisory Boardsrc
  • Other Not independent as a director; resident in New Jersey, per the 2026 circularsrc

The promise ledger

No promise on the record yet: the research routine has not scored this company's guidance.

Sources

9
  1. Filing Helus Pharma press release: appoints Michael Halstead as CEO (Ex-99.1 to 6-K, acc 0001062993-26-003976) · 2026-08-03
  2. Filing Cybin Inc. management information circular for the 2026 annual and special meeting, dated 2026-08-18 (Ex-99 to 6-K, acc 0001833141-26-000067) · 2026-08-18
  3. Filing Helus Pharma press release: Regina Donohue as Chief People Officer, Suresh Durgam to SAB (Ex-99.1 to 6-K, acc 0001833141-26-000061) · 2026-08-18
  4. Filing Helus Pharma press release: results of 2026-09-22 annual and special meeting (Ex-99.1 to 6-K, acc 0001833141-26-000081) · 2026-09-22
  5. Filing Form 3, Michael Halstead (reporting CIK 1521548), Chief Executive Officer (acc 0000912282-26-001277) · 2026-09-17
  6. Filing Form 4, Michael Halstead, open-market purchase 2026-09-21 (acc 0000912282-26-001293) · 2026-09-21
  7. Filing Cybin Inc. audited consolidated financial statements FY ended 2026-03-31 (Ex-99.2 to 40-F, acc 0001833141-26-000046) · 2026-06-29
  8. Filing Intra-Cellular Therapies DEF 14A 2024 (acc 0001628280-24-018986) · 2024-04-29
  9. Filing Intra-Cellular Therapies DEF 14A 2016 (acc 0001193125-16-564211) · 2016-04-28